October 1, 2021 | Targeted Therapies in Oncology

Understanding irAEs Is Vital for IO Combo Use in HCC

October 05, 2021

Clinical Articles

In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Second-Line Cemiplimab Improves Survival and Quality of Life in Cervical Squamous Cell Carcinoma

October 05, 2021

Clinical Articles

Results from the EMPOWER-Cervical 1/ GOG-3016/ENGOT-cx9 trial led the FDA to grant priority review to cemiplimab as treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

Daratumumab Combination Therapy Established Standard of Care for Newly Diagnosed Multiple Myeloma

October 04, 2021

Clinical Articles

A recent presentation during the 18th International Myeloma Workshop focused on updated efficacy and safety data for daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone after nearly 5 years of median follow-up in the phase 3 MAIA study.

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

October 03, 2021

Clinical Articles

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Greater Tolerability Is Seen With Iberdomide in Multiple Myeloma

October 03, 2021

Clinical Articles

Results from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations.

Navigating Opioids and Other Strategies for Managing Cancer Pain

October 02, 2021

Clinical Articles

Up to 60% of patients undergoing active treatment and a third of cancer survivors report significant pain stemming either from their cancer itself or their cancer treatments. The most common treatment for significant cancer- related pain is opioid medication.